Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Futura Medical ( (GB:FUM) ) has provided an update.
Futura Medical plc has announced the appointment of Alex Duggan as interim CEO, following board changes and the resignation of Angela Hildreth as Finance Director and COO. Duggan, with extensive leadership experience, will lead a strategic review of the company’s operations, focusing on the sales and marketing strategies for Eroxon, which has shown slower than expected sales momentum. The review aims to refine the company’s commercial plans and maximize value for stakeholders, with an update expected by late September.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a developer of innovative sexual health products, with a focus on topically delivered gel formulations. Their lead product, Eroxon, is a clinically proven topical gel for the treatment of Erectile Dysfunction (ED), offering a unique over-the-counter solution that works within ten minutes. Futura has established distribution partnerships in major markets, including the US and Europe, to address significant unmet needs in the ED market.
Average Trading Volume: 758,424
Technical Sentiment Signal: Sell
Current Market Cap: £36.6M
See more data about FUM stock on TipRanks’ Stock Analysis page.